A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas
Crossref DOI link: https://doi.org/10.1007/s11060-017-2469-x
Published Online: 2017-05-16
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kumthekar, Priya
Grimm, Sean
Chandler, James
Mehta, Minesh
Marymont, Maryanne
Levy, Robert
Muro, Kenji
Helenowski, Irene
McCarthy, Katie
Fountas, Leanne
Raizer, Jeffrey
Funding for this research was provided by:
Cephalon (US)
License valid from 2017-05-16